-
2024-519421-37-00
5
2025-08-28
Major Depressive Disorder
-
2024-517727-39-00
5
2025-07-28
Covid-19 at high risk of progression to severe illness.
-
2024-516684-82-00
4
2025-07-21
Generalized Anxiety Disorder
-
2024-516834-36-00
5
2025-07-08
Locally recurrent unresectable or metastatic TNBC with tumors expressi
-
2024-512084-31-00
6
2025-06-24
Patients requiring emergency abdominal or body CT with eGFR 15-45 ml/m
-
2023-508196-36-00
4
2025-05-27
Follicular lymphoma
-
2023-506327-29-00
5
2025-05-14
Non-Small Cell Lung Cancer
-
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
-
2024-511652-40-00
5
2025-02-05
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2024-520288-15-00
6
2025-01-25
Metastatic or locally advanced inoperable colorectal cancer
-
2024-512475-12-01
6
2024-11-27
We are investigating the efficacy and safety of enhanced thromboprophy
-
2024-519263-18-00
6
2024-11-26
Participants are pregnant women found to carry Group G or C Streptococ
-
2024-517478-68-01
4
2024-11-06
Advanced Cancer
-
2024-518816-38-00
6
2024-11-05
Patients of the pediatric emergency room at Oulu University Hospital w
-
2024-517508-12-00
6
2024-10-24
Undergoing hysterectomy
-
2023-507353-15-00
5
2024-09-10
idiopathic pulmonary fibrosis (IPF)
-
2023-510415-19-00
4
2024-08-28
Acute Myeloid Leukemia
-
2023-508183-29-00
6
2024-08-07
Risk factors of cardiovascular disease
-
2024-515914-41-00
4
2024-07-05
Chronic Lung Disease
-
2023-508147-43-00
6
2024-05-31
Venous thromboembolism (in surgical patients)
-
2023-506150-21-00
4
2024-05-29
Celiac Disease
-
2023-507871-23-00
5
2024-05-27
Relapsed/Refractory Multiple Myeloma
-
2023-504923-20-00
5
2024-04-04
Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
-
2022-500531-36-00
4
2024-02-02
Type 1 diabetes mellitus